Cryptococcal chest wall mass and rib osteomyelitis associated with the use of fingolimod: A case report and literature review

Being introduced in 2010, fingolimod was among the first oral therapies for relapsing multiple sclerosis (MS). Since that time, postmarketing surveillance has noted several case reports of various cryptococcal infections associated with fingolimod use. To date, approximately 15 such case reports hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Carpenter, Kent, Etemady-Deylamy, Ali, Costello, Victoria, Khasawneh, Mohammad, Chamberland, Robin, Tian, Katherine, Donlin, Maureen, Moreira-Walsh, Brenda, Reisenbichler, Emily, Abate, Getahun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491343/
https://www.ncbi.nlm.nih.gov/pubmed/36160166
http://dx.doi.org/10.3389/fmed.2022.942751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491343/
https://www.ncbi.nlm.nih.gov/pubmed/36160166
http://dx.doi.org/10.3389/fmed.2022.942751

Ejemplares similares